Restricted accessResearch articleFirst published online 2012-6
Effects of positive modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors in a benzodiazepine-induced deficit of spatial discrimination in mice
Imbalance between GABAergic and glutamatergic neurotransmission has been recently hypothesized to trigger memory decline related either to ageing or to Alzheimer’s disease (AD). Thereby, benzodiazepine-induced anterograde amnesia has been construed as a model of hippocampal-related cognitive dysfunctions. Since spatial memory is altered both by ageing and by benzodiazepines such as alprazolam, we investigated the pharmacological sensitivity of alprazolam-induced deficit in a delayed spatial discrimination (SD) task, notably with positive allosteric modulators of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors. We showed that alprazolam (0.1 mg/kg intraperitoneally) induced memory impairments as compared with vehicle-treated mice. The oral administration of modulators of AMPA receptors (IDRA-21: 10 mg/kg; S18986: 3 and 10 mg/kg) reversed the alprazolam-induced deficits. This study is first to show evidence that reference treatments of AD, such as memantine (a NMDA receptor antagonist) at 3 mg/kg per os (po) and donepezil (an acetylcholinesterase inhibitor) at 1 mg/kg po, also reversed the alprazolam-induced amnesia. Given such results, the SD task emerges as a valuable novel task to screen pro-cognitive compounds. Thus, we highlight the efficacy of modulators of AMPA-type glutamate receptors to counteract alprazolam-induced spatial deficits. These results could be viewed alongside the imbalance between excitation and inhibition observed during normal and pathological ageing.
AraiAKesslerMXiaoPAmbros-IngersonJRogersGLynchG (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res638: 343–346.
2.
AraiACXiaYFSuzukiE (2004) Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. Neuroscience123: 1011–1024.
3.
AronicaEDicksonDWKressYMorrisonJHZukinRS (1998) Non-plaque dystrophic dendrites in Alzheimer hippocampus: a new pathological structure revealed by glutamate receptor immunocytochemistry. Neuroscience82: 979–991.
4.
AutaJFaustWBLambertPGuidottiACostaEMoerschbaecherJM (1995) Comparison of the effects of full and partial allosteric modulators of GABA(A) receptors on complex behavioral processes in monkeys. Behav Pharmacol6: 323–332.
5.
BarnesCADanyszWParsonsCG (1996) Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur J Neurosci8: 565–571.
6.
BarnesCAMeltzerJHoustonFOrrGMcGannKWenkGL (2000) Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. Neuroscience99: 17–23.
7.
BartusRTDeanRLBeerBLippaAS (1982) The cholinergic hypothesis of geriatric memory dysfunction. Science217: 408–414.
8.
BeracocheaD (2006) Anterograde and retrograde effects of benzodiazepines on memory. Sci World J6: 1460–1465.
9.
BeracocheaDBoucardATrocme-ThibiergeCMorainP (2008) Improvement of contextual memory by S 24795 in aged mice: comparison with memantine. Psychopharmacology196: 555–564.
10.
BeracocheaDPhilippinJNMeunierSMorainPBernardK (2007) Improvement of episodic contextual memory by S 18986 in middle-aged mice: comparison with donepezil. Psychopharmacology193: 63–73.
11.
Bertaina-AngladeVEnjuanesEMorillonDDrieu La RochelleC (2006) The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. J Pharmacol Toxicol Methods54: 99–105.
12.
BlackMD (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology179: 154–163.
13.
BontempiBWhelanKTRisbroughVBLloydGKMenzaghiF (2003) Cognitive enhancing properties and tolerability of cholinergic agents in mice: a comparative study of nicotine, donepezil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropsychopharmacology28: 1235–1246.
14.
BuccafuscoJJWeiserTWinterKKlinderKTerryAV (2004) The effects of IDRA-21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology46: 10–22.
15.
ChalmersDTDewarDGrahamDIBrooksDNMcCullochJ (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc Natl Acad Sci U S A87: 1352–1356.
16.
CélérierAPiérardCRachbauerDSarrieauABéracochéaD (2004) Contextual and serial discriminations: a new learning paradigm to assess simultaneously the effects of acute stress on retrieval of flexible or stable information in mice. Learn Mem11: 196–204.
17.
ChenYByrnePCrawfordJD (2011) Time course of allocentric decay, egocentric decay, and allocentric-to-egocentric conversion in memory-guided reach. Neuropsychologia49: 49–60.
18.
CreeleyCWozniakDFLabruyereJTaylorGTOlneyJW (2006) Low doses of memantine disrupt memory in adult rats. J Neurosci26: 3923–3932.
19.
DanyszWParsonsCG (2003) The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer’s disease: preclinical evidence. Int J Geriatr Psychiatry18: S23–S32.
20.
DanyszWParsonsCGMobiusHJStofflerAQuackG (2000) Neuroprotective and symptomatological action of memantine relevant for Alzheimer’s disease—a unified glutamatergic hypothesis on the mechanism of action. Neurotox Res2: 85–97.
21.
Destot-WongKDLiangKGuptaSKFavraisGSchwendimannLPansiotJ. (2009) The AMPA receptor positive allosteric modulator, S18986, is neuroprotective against neonatal excitotoxic and inflammatory brain damage through BDNF synthesis. Neuropharmacology57: 277–286.
EustacheFGiffardBRauchsGChetelatGPiolinoPDesgrangesB (2006) Alzheimer’s disease and human memory. Rev Neurol162: 929–939.
24.
FerriCPPrinceMBrayneCBrodatyHFratiglioniLGanguliM. (2005) Global prevalence of dementia: a Delphi consensus study. Lancet366: 2112–2117.
25.
FletcherEJLodgeD (1996) New developments in the molecular pharmacology of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate and kainate receptors. Pharmacol Ther70: 65–89.
26.
FrancisPT (2005) The interplay of neurotransmitters in Alzheimer’s disease. CNS Spectr11(18): 6–9.
27.
FrancisPTPalmerAMSnapeMWilcockGK (1999) The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry66: 137–147.
28.
FrancisPTSimsNRProcterAWBowenDM (1993) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: investigative and therapeutic perspectives. J Neurochem60: 1589–1604.
29.
GiustiPGuidettiGCostaEGuidottiA (1991) The preferential antagonism of pentylenetetrazole proconflict responses differentiates a class of anxiolytic benzodiazepines with potential antipanic action. J Pharmacol Exp Ther257: 1062–1068.
30.
HoganJBHodgesDBJrLelasSGilliganPJMcElroyJFLindnerMD (2005) Effects of CRF1 receptor antagonists and benzodiazepines in the Morris water maze and delayed nonmatching to position tests. Psychopharmacology178: 410–419.
31.
IkonomovicMDSheffieldRArmstrongDM (1995) AMPA-selective glutamate receptor subtype immunoreactivity in the aged human hippocampal formation. J Comp Neurol359: 239–252.
32.
IkonomovicMDMizukamiKWardeDSheffieldRHamiltonRWentholdRJArmstrongDM (1999) Distribution of glutamate receptor subunit NMDAR1 in the hippocampus of normal elderly and patients with Alzheimer’s disease. Exp Neurol160: 194–204.
33.
LebrunCPillièreELestageP (2000) Effects of S 18986-1, a novel cognitive enhancer, on memory performances in an object recognition task in rats. Eur J Pharmacol401: 205–212.
LestageP (2000) Pharmacologic treatment for cognitive disorders: an update. Therapie55: 507–512.
36.
LindnerMDHoganJBHodgesDBJrOrieAFChenPCorsaJA. (2006) Donepezil primarily attenuates scopolamine-induced deficits in psychomotor function, with moderate effects on simple conditioning and attention, and small effects on working memory and spatial mapping. Psychopharmacology (Berl)188: 629–640.
37.
LockhartBIopFClosierMLestageP (2000) (S)-2,3-dihydro-[3,4]cyclopentano-1,2,4-benzothiadiazine-1,1-dioxide: (S18986-1) a positive modulator of AMPA receptors enhances (S)-AMPA-mediated [3H]noradrenaline release from rat hippocampal and frontal cortex slices. Eur J Pharmacol401: 145–153.
38.
LockhartBPLestagePJ (2003) Cognition enhancing or neuroprotective compounds for the treatment of cognitive disorders: why? when? which?Exp Gerontol38: 119–128.
39.
LockrowJBogerHBimonte-NelsonHGranholmAC (2011) Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res221: 610–622.
40.
LoweSLFrancisPTProcterAWPalmerAMDavisonANBowenDM (1988) Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain111: 785–799.
41.
Martinez-CoriaHGreenKNBillingsLMKitazawaMAlbrechtMRammesG. (2010) Memantine improves cognition and reduces Alzheimer’s-like neuropathology in transgenic mice. Am J Pathol176: 870–880.
42.
MinkevicieneRBanerjeePTanilaH (2004) Memantine improves spatial learning in a transgenic mouse model of Alzheimer’s disease. J Pharmacol Exp Ther311: 677–682.
43.
NyakasCGranicIHalmyLGBanerjeePLuitenPG (2011) The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine. Behav Brain Res221: 594–603.
44.
PalopJJChinJRobersonEDWangJThwinMTBien-LyN. (2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron55: 697–711.
45.
ParsonsCGStöfflerADanyszW (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology53: 699–723.
46.
RissmanRABennettDAArmstrongDM (2004) Subregional analysis of GABA(A) receptor subunit mRNAs in the hippocampus of older persons with and without cognitive impairment. J Chem Neuroanat28: 17–25.
47.
RissmanRADe BlasALArmstrongDM (2007) GABA(A) receptors in aging and Alzheimer’s disease. J Neurochem103: 1285–1292.
48.
RobbinsTWMurphyER (2006) Behavioural pharmacology: 40+ years of progress, with a focus on glutamate receptors and cognition. Trends Pharmacol Sci27: 141–148.
49.
RogawskiMAWenkGL (2003) The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev9: 275–308.
50.
RosiSGiovanniniMGLestagePJMuñozCCorteLDPepeuG (2004) S 18986, a positive modulator of AMPA receptors with cognition-enhancing properties, increases ACh release in the hippocampus of young and aged rat. Neurosci Lett361: 120–123.
51.
RuanoDAraujoFRevillaEVelaJBergisOVitoricaJ (2000) GABAA and alpha-amino-3-hydroxy-5-methylsoxazole-4-propionate receptors are differentially affected by aging in the rat hippocampus. J Biol Chem275: 19585–19593.
SeltzerB (2007) Donepezil: an update. Expert Opin Pharmacother8: 1011–1023.
54.
SinghNSharmaASinghM (1998) Possible mechanism of alprazolam-induced amnesia in mice. Pharmacology56: 46–50.
55.
SunBHalabiskyBZhouYPalopJJYuGMuckeLGanL (2009) Imbalance between GABAergic and glutamatergic transmission impairs adult neurogenesis in an animal model of Alzheimer’s disease. Cell Stem Cell5: 624–633.
56.
ThiebotMH (1985) Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci Biobehav Rev9: 95–100.
57.
ThompsonDMGuidottiADiBellaMCostaE (1995) 7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA-21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys. Proc Natl Acad Sci U S A92: 7667–7671.
58.
Van DamDAbramowskiDStaufenbielMDe DeynPP (2005) Symptomatic effects of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology180: 177–190.
59.
VandesquilleMKrazemALouisCLestagePBeracocheaD (2011) S18986 reverses spatial working memory impairments in aged mice: comparison with memantine. Psychopharmacology (Berl), 215: 709–720.
60.
VelaJGutierrezAVitoricaJRuanoD (2003) Rat hippocampal GABAergic molecular markers are differentially affected by ageing. J Neurochem85: 368–377.
61.
WanHWarburtonECZhuXOKoderTJParkYAggletonJP. (2004) Benzodiazepine impairment of perirhinal cortical plasticity and recognition memory. Eur J Neurosci20: 2214–2224.
62.
WestphalenRIScottHLDoddPR (2003) Synaptic vesicle transport and synaptic membrane transporter sites in excitatory amino acid nerve terminals in Alzheimer’s disease. J Neural Transm110: 1013–1027.
63.
YamadaKA (2000) Therapeutic potential of positive AMPA receptor modulators in the treatment of neurological disease. Expert Opin Investig Drugs9: 765–778.
64.
YoshiikeYKimuraTYamashitaSFurudateHMizorokiTMurayamaM. (2008) GABA(A) receptor-mediated acceleration of aging-associated memory decline in APP/PS1 mice and its pharmacological treatment by picrotoxin. PLoS One3: e3029.
65.
ZajaczowskiWFrankiewiczTParsonsCGDanyszW (1997) Uncompetitive NMDA receptor antagonists attenuate NMDA induced impairment of passive avoidance learning and LTP. Neuropharmacology36: 961–976.
66.
ZhaoCDengWGageFH (2008) Mechanisms and functional implications of adult neurogenesis. Cell132: 645–660.
67.
ZivkovicIThompsonDMBertolinoMUzunovDDiBellaMCostaE. (1995) 7-Chloro-3-methyl-3-4-dihydro-2H-1,2,4 benzothiadiazine S,S-dioxide (IDRA-21): a benzothiadiazine derivative that enhances cognition by attenuating DL-alpha-amino-2,3-dihydro-5-methyl-3-oxo-4-isoxazolepropanoic acid (AMPA) receptor desensitization. J Pharmacol Exp Ther272: 300–309.
68.
ZoladzPRCampbellAMCollinRPSchaeferDDanyszWDiamondDM (2006) Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav85: 298–306.
